Role of a subdominant H-2K(d)-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection

Virology

Volumn 244, Issue 2, 1998, Pages 427-441

  Newmaster, Romnie S ^a   Mylin, Lawrence M ^a   Fu, Tong Ming ^a   Tevethia, Satvir S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antigen presentation; CTL; Subdominant CTL epitope; SV40 tumor antigen; Tumor immunity

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL TRANSFORMATION; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SPECIFICITY; VIRUS GENOME; VIRUS TRANSFORMATION;

ANIMALIA; DNA VIRUSES; VACCINIA; VACCINIA VIRUS;

EID: 0032503228     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9148     Document Type: Article

References (77)

1. Abramczuk J., Pan S., Maul G., Knowles B. B. Tumor induction by Simian Virus 40 in mice is controlled by long-term persistence of the viral genome and the immune response of the host. J. Virol. 49:1984;540-548.
2. Bacik I., Cox J. H., Anderson R., Yewdell J. W., Bennink J. R. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl terminus of the peptide. J. Immunol. 152:1994;381-387.
3. +. J. Virol. 71:1997;3534-3544.
4. Bright R. K., Beames B., Shearer M. H., Kennedy R. C. Protection against a lethal tumor challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large T antigen. Cancer Res. 56:1996;1126-1130.
5. Brinster R. L., Chen H. Y., Messing A., van Dyke T., Levine A. J., Palmiter R. D. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell. 37:1984;367-379.
6. Campbell A. E., Foley F. L., Tevethia S. S. Demonstration of multiple antigenic sites of the SV40 transplantation rejection antigen by using cytotoxic T lymphocyte clones. J. Immunol. 130:1983;490-492.
7. Chen W., Khilko S., Fecondo J., Margulies D. H., McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J. Exp. Med. 180:1994;1471-1483.
8. b-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J. Virol. 66:1992;440-447.
9. b. J. Immunol. 148:1992;3012-3020.
10. Deng Y., Yewdell J. W., Eisenlohr L. C., Bennink J. R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158:1997;1507-1515.
11. Drapkin M. S., Apella E., Law L. W. Immunogenic properties of a soluble tumor specific transplantation antigen induced by simian virus 40. J. Natl. Cancer Inst. 52:1974;259-264.
12. Dunn T. B., Potter M. A transplantable mast-cell neoplasm in the mouse. J. Natl. Cancer Inst. 18:1957;587-601.
13. Eisenlohr L. C., Bacik I., Bennink J. R., Bernstein K., Yewdell J. W. Expression of a membrane protease enhances presentation of endogenous antigen to MHC class I-restricted T lymphocytes. Cell. 71:1992;963-972.
14. Fanning E. Simian virus 40 large T antigen; the puzzle, the pieces, and the emerging picture. J. Virol. 66:1992;1289-1293.
15. Feltkamp M. C. W., Vreugdenhil G. R., Vierboom M. P. M., Ras E., van der Burg S. H., Schegget J., Melief C. J. M., Kast W. M. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:1995;2638-2642.
16. b. J. Immunol. 129:1982;2368-2371.
17. Flyer D. C., Pretell J., Campbell A. E., Liao W. S. L., Tevethia M. J., Taylor J. M., Tevethia S. S. Biology of simian virus 40 (SV40) transplantation antigen (TrAg). X. Tumorigenic potential of mouse cells transformed by SV40 in high responder C57BL/6 mice and correlation with the persistence of SV40 TrAg, early proteins and viral sequences. Virology. 131:1983;207-220.
18. Fu T.-M., Friedman A., Ulmer J. B., Liu M. A., Donnelly J. J. Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71:1997;2715-2721.
19. Fu T.-M., Mylin L. M., Schell T. D., Bacik I., Russ G., Yewdell J. W., Bennink J. R., Tevethia S. S. An endoplasmic reticulum targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 T antigen cytotoxic T lymphocyte epitope. J. Virol. 72:1998.
20. Gooding L. R. Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: Studies employing recombinants within the H-2 complex. J. Immunol. 122:1979;1002-1008.
21. k. J. Immunol. 129:1982;1306-1312.
22. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:1985;115-122.
23. Hill A. B., Lee S. P., Haurum J. S., Murray N., Yao Q.-Y., Rowe M., Signoret N., Rickinson A. B., McMichael A. J. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised. J. Exp. Med. 181:1995;2221-2228.
24. 1. Proc. Natl. Acad. Sci. USA. 75:1978;3055-3059.
25. 2. J. Gen. Virol. 44:1979;287-296.
26. Jennings S. R., Rice P. L., Kloszewski E. D., Anderson R. W., Thompson D. L., Tevethia S. S. Effect of herpes simplex virus types 1 and 2 on surface expression of class I major histocompatibility complex antigens on infected cells. J. Virol. 56:1985;757-766.
27. +. J. Exp. Med. 183:1996;791-800.
28. Kagi D., Ledermann B., Burki K., Zinkernagel R. M., Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14:1996;207-232.
29. Kalderon D., Smith A. E. In vitro. Virology. 139:1984;109-137.
30. Kit S., Kurimura T., Dubbs D. R. Transplantable mouse tumor line induced by injection of SV40-transformed mouse kidney cells. Int. J. Cancer. 4:1969;384-392.
31. Knowles B. B., Koncar M., Pfizenmaier K., Solter D., Aden D. P., Trinchieri G. Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen. J. Immunol. 122:1979;1798-1806.
32. Knowles B. B., McCarrick J., Fox N., Solter D., Damjanov I. Osteosarcomas in transgenic mice expressing an α-amylase-SV40 T-antigen hybrid gene. Am. J. Pathol. 137:1990;259-262.
33. Law L. W., Takemoto K. K., Rogers M. J., Ting R. C. Induction of simian virus 40 (SV40) transplantation immunity in mice by SV40 transformed cells of various species. J. Natl. Cancer Inst. 59:1977;1523-1526.
34. Levine A. J. The SV40 large tumor antigen. Molecular Biology of Chromosome Function. 1989;Springer-Verlag, New York. p. 71-96.
35. Lill N. L., Tevethia M. J., Hendrickson W. G., Tevethia S. S. Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. J. Exp. Med. 176:1992;449-457.
36. b. J. Virol. 69:1995;3134-3146.
37. Livingston D. M., Bradley M. K. The simian virus 40 large T antigen. A lot packed into a little. Mol. Biol. Med. 4:1987;63-80.
38. dd. J. Immunol. 130:1983;463-470.
39. b. J. Virol. 69:1995a;6665-6677.
40. b. Virology. 208:1995b;159-172.
41. Niedermann G., Butz S., Ihlenfeldt H. G., Grimm R., Lucchiari M., Hoschutzky H., Jung G., Maier B., Eichmann K. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity. 2:1995;289-299.
42. Oldstone M. B. A., Lewicki H., Borrow P., Hudrisier D., Gairin J. E. Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J. Virol. 69:1995;7423-7429.
43. Ornitz D. M., Hammer R. E., Messing A., Palmiter R. D., Brinster R. L. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science. 238:1987;188-193.
44. Oukka M., Manuguerra J. C., Livaditis N., Tourdot S., Riche N., Vergnon I., Cordopatis P., Kosmatopoulos K. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 157:1996;3039-3045.
45. Palmiter R. D., Chen H. Y., Messing A., Brinster R. L. SV40 enhancer and large T antigen are instrumental in development of choroid plexus tumors in transgenic mice. Nature. 316:1985;457-460.
46. Pan S., Abramczuk J., Knowles B. B. Immune control of SV40-induced tumors in mice. Int. J. Cancer. 39:1987;722-728.
47. Pfizenmaier K., Pan S. H., Knowles B. B. Preferential H-2 association in cytotoxic T cell responses to SV40 tumor-associated specific antigens. J. Immunol. 124:1980;1888-1891.
48. Pfizenmaier K., Trinchieri G., Solter D., Knowles B. B. Mapping of H-2 genes associated with T cell-mediated cytotoxic responses to SV40-tumour-associated specific antigens. Nature. 274:1978;691-693.
49. Rammensee H.-G., Falk K., Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:1993;213-244.
50. Restifo N. P., Esquivel F., Kawakami Y., Yewdell J. W., Mule J. J., Rosenberg S. A., Bennink J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:1993;265-272.
51. d. J. Immunol. 157:1996;3550-3558.
52. Shearer M. H., Bright R. K., Lanford R. E., Kennedy R. C. Immunization of mice with baculovirus-derived recombinant SV40 large tumour antigen induces protective tumour immunity to a lethal challenge with SV40-transformed cells. Clin. Exp. Immunol. 91:1993;266-271.
53. Sherman L. A., Burke T. A., Biggs J. A. Extracellular processing of peptide antigens that bind Class I major histocompatibility molecules. J. Exp. Med. 175:1992;1221-1226.
54. Sparer T. E., Wynn S. G., Clark D. J., Kaplan J. M., Cardoza L. M., Wadsworth S. C., Smith A. E., Gooding L. R. Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. J. Virol. 71:1997;2277-2284.
55. b. Virology. 171:1989;205-213.
56. Tanaka Y., Tevethia M. J., Kalderon D., Smith A. E., Tevethia S. S. Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virology. 162:1988;427-436.
57. Tanaka Y., Tevethia S. S. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J. Immunol. 140:1988;4348-4354.
58. Tanaka Y., Tevethia S. S. Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. Intervirology. 31:1990;197-202.
59. Tevethia M. J., Ripper L. W., Tevethia S. S. A simple qualitative spot complementation test for temperature sensitive mutants of SV40. Intervirology. 3:1974a;245-255.
60. Tevethia S. S. Immunology of simian virus 40. Viral Oncology. 1980;Raven Press, New York. p. 581-601.
61. Tevethia S. S. Recognition of Simian Virus 40 T antigen by cytotoxic T lymphocytes. Mol. Biol. Med. 7:1990;83-96.
62. Tevethia S. S., Blasecki J. W., Waneck G., Goldstein A. L. Requirement of thymus-derived θ-positive lymphocytes for rejection of DNA virus (SV40) tumors in mice. J. Immunol. 113:1974b;1417-1423.
63. Tevethia S. S., Flyer D. C., Tjian R. Biology of Simian Virus 40 (SV40) transplantation antigen (TrAg). VI. Mechanism of induction of SV40 transplantation immunity in mice by purified SV40 T antigen (D2 protein). Virology. 107:1980;13-23.
64. Tevethia S. S., Greenfield R. S., Flyer D. C., Tevethia M. J. SV40 transplantation antigen: relationship to SV40-specific proteins. Cold Spring Harbor Symp. Quant. Biol. 44:1979;235-242.
65. Tevethia S. S., McMillan V. L. Acquisition of malignant properties by SV40-transformed mouse cells: Relationship to Type-C viral antigen expression. Intervirology. 3:1974;269-276.
66. Tevethia S. S., Waneck G., Tevethia M. J. Immune response of athymic nude mice to Papovavirus SV40 tumor-associated antigens. Int. J. Cancer. 19:1977;700-706.
67. Townsend A., Bastin J., Gould K., Brownlee G., Andrew M., Coupar B., Boyle D., Chan S., Smith G. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168:1988;1211-1224.
68. Trinchieri G., Aden D. P., Knowles B. B. Cell-mediated cytotoxicity to SV40-specific tumour-associated antigens. Nature. 261:1976;312-314.
69. van der Most R. G., Concepcion R. J., Oseroff C., Alexander J., Southwood S., Sidney J., Chesnut R. W., Ahmed R., Sette A. Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J. Virol. 71:1997;5110-5114.
70. van der Most R. G., Sette A., Oseroff C., Alexander J., Murali-Krishna K., Lau L. L., Southwood S., Sidney J., Chesnut R. W., Matloubian M., Ahmed R. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157:1996;5543-5554.
71. b. J. Immunol. 157:1996;5555-5562.
72. Ye X., McCarrick J., Jewett L., Knowles B. B. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA. 91:1994;3916-3920.
73. Yellen-Shaw A. J., Wherry E. J., Dubois G. C., Eisenlohr L. C. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J. Immunol. 158:1997;3227-3234.
74. Yewdell J. W., Esquivel F., Arnold D., Spies T., Eisenlohr L. C., Bennink J. R. Presentation of numerous viral peptides to mouse major histocompatibility complex (MHC) class I-restricted T lymphocytes is mediated by the human MHC-encoded transporter or by a hybrid mouse-human transporter. J. Exp. Med. 177:1993;1785-1790.
75. Zarling J. M., Tevethia S. S. Transplantation immunity to Simian Virus 40-transformed cells in tumor-bearing mice. I. Development of cellular immunity to Simian Virus 40 tumor-specific transplantation antigens during tumorigenesis by transplanted cells. J. Natl. Cancer Inst. 50:1973a;137-147.
76. Zarling J. M., Tevethia S. S. Transplantation immunity to Simian Virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection. J. Natl. Cancer Inst. 50:1973b;149-157.
77. Zerrahn J., Utermohlen O., Warnecke G., Deppert W., Lehmann-Grube F. Protective immunity in BALB/c mice against the simian virus 40-induced mKSA tumor resulting from injection of recombinant large T antigen. J. Immunol. 156:1996;3919-3924.